Home Stock

Stock Research: Sawai Pharmaceutical

Independent, rules-based stock research to judge this stock's true performance: Cut through market noise and find high-growth or high-value gems from 8,000+ stocks worldwide.

Sawai Pharmaceutical

TYO:4887 JP3323050009
89
  • Value
    90
  • Growth
    81
  • Safety
    Safety
    45
  • Combined
    79
  • Sentiment
    92
  • 360° View
    360° View
    89
Unlock
What factors are driving this 360° View?
Subscribe to View
Company Description

Sawai Group Holdings Co Ltd manufactures and sells medical and over-the-counter drugs. They operate in pharmaceutical and medical device manufacturing and sales, and R&D. Key regions include Japan and America. In the last fiscal year, the company had 3310 employees, a market cap of $1489 million, profits of $376 million, and revenue of $1261 million.

more

ANALYSIS: With an Obermatt 360° View of 89 (better than 89% compared with alternatives) for 2026, overall professional sentiment and financial characteristics for the stock Sawai Pharmaceutical are very positive. The 360° View is based on consolidating four consolidated indicators, with all but one indicator above average for Sawai Pharmaceutical. The consolidated Value Rank has an attractive rank of 90, which means that the share price of Sawai Pharmaceutical is on the lower side compared with the typical size in indicators such as revenues, profits, and invested capital. This means the stock price is lower than for 90% of alternative stocks in the same industry. The consolidated Growth Rank has a good rank of 81, which means that the company experiences above-average growth momentum when looking at financial metrics such as revenue, profit, and invested capital growth, as well as stock returns. In addition, professional market sentiment is above average compared with other stock investment alternatives with a Sentiment Rank of 92. But the company’s financing is risky with a Safety rank of 45. This means 55% of comparable companies have a safer financing structure than Sawai Pharmaceutical. ...read more

more
Strongest Rank Revenue Growth
Weakest Rank Pro Holdings
Country Japan
Industry Pharmaceuticals
Size Large
Website sawaigroup.holdings
Index
Sawai Pharmaceutical stock price by TradingView. Not sourced by Obermatt.
Similar Add to Watchlist Similar See Similar Stocks
The higher the 360° View, the better the stock performed against its peers, considering all metrics. The 360° View represents an average of the other 5 ranks and is then scaled to a rank from 1 to 100. The shaded values are illustrative only.
Last update: 20-May-2026.

Make Sense of the Ranks

The higher, the better. For every stock, we judge its performance against its peers and rank it on a scale of 1 to 100. These ranks are percentiles: a rank of 75 means the company outperforms 75% of its peers in that specific area. The higher the rank, the better the stock stacks up against its peers.

Value
Identifies how good a value the stock is.
Good Value Expensive
Combined
Consolidated view across Value, Growth, and Safety.
Good Tread Carefully
Growth
Shows a company's growth potential.
High Growth Tough Times
Sentiment
Shows what the market thinks of a stock.
Positive Sentiment Skepticism
Safety
Safety
Assesses how financially secure a company is.
Well-Financed High Leverage
360° View
360° View
Holistic stock analysis: all key non-/financial metrics
Good Watch Out

Detailed and Historical Ranks

Deep dive into 15 detailed ranks and 3 years of history. Unlock the analysis.

Unlock Ranks

Unlock all 15 detailed ranks and historical data for 6,500+ stocks.

Subscribe to Unlock
Metrics Current 2025 2024 2023
Value
90 86 92 100
Growth
81 59 39 51
Safety
Safety
45 61 72 70
Sentiment
92 86 82 25
360° View
360° View
89 98 98 87
Unlock Similar Stocks

Unlock all 15 detailed ranks and historical data for 6,500+ stocks.

Subscribe to Unlock
Metrics Current 2025 2024 2023
Analyst Opinions
50 40 44 28
Opinions Change
50 70 82 50
Pro Holdings
n/a 92 82 39
Market Pulse
92 65 54 44
Sentiment
92 86 82 25
Unlock Similar Stocks

Unlock all 15 detailed ranks and historical data for 6,500+ stocks.

Subscribe to Unlock
Metrics Current 2025 2024 2023
Value
90 86 92 100
Growth
81 59 39 51
Safety Safety
45 61 72 70
Combined
79 86 92 94
Unlock Similar Stocks

Unlock all 15 detailed ranks and historical data for 6,500+ stocks.

Subscribe to Unlock
Metrics Current 2025 2024 2023
Price vs. Sales (P/S)
84 76 91 97
Price vs. Earnings (P/E)
38 81 74 97
Price vs. Book (P/B)
80 78 71 93
Dividend Yield
85 65 82 92
Value
90 86 92 100
Unlock Similar Stocks

Unlock all 15 detailed ranks and historical data for 6,500+ stocks.

Subscribe to Unlock
Metrics Current 2025 2024 2023
Revenue Growth
26 36 37 43
Profit Growth
85 79 50 81
Capital Growth
86 34 18 24
Stock Returns
50 74 77 49
Growth
81 59 39 51
Unlock Similar Stocks

Unlock all 15 detailed ranks and historical data for 6,500+ stocks.

Subscribe to Unlock
Metrics Current 2025 2024 2023
Leverage
34 27 33 36
Refinancing
70 76 89 89
Liquidity
55 59 59 53
Safety Safety
45 61 72 70

Similar Stocks

Discover high‑ranked alternatives to Sawai Pharmaceutical and broaden your portfolio horizons.

Inpex

TYO:1605
Country: Japan
Industry: Oil & Gas Production
Size: X-Large
Full Stock Analysis

Toyobo

TYO:3101
Country: Japan
Industry: Commodity Chemicals
Size: Large
Full Stock Analysis

Tokyo Gas

TYO:9531
Country: Japan
Industry: Gas Utilities
Size: Large
Full Stock Analysis

Macnica Holdings

TYO:3132
Country: Japan
Industry: Technology Distributors
Size: Large
Full Stock Analysis

Frequently Asked
Questions

This is a high-quality, high-growth stock with positive sentiment. However, the financing is on the riskier side. It is best for a growth-focused investor willing to accept higher financial risk for potentially higher shareholder returns.

Obermatt provides unbiased stock analysis as a completely independent third party. We have no conflicts of interest with individual stock titles. Our data-driven analysis is based on algorithms honed over twelve years, giving you analysis that is free from personal bias and conflicts of interest.

The 360° View Rank indicates a company's overall performance across all major financial and non-financial metrics tracked by Obermatt. A 360° View Rank of 75 means the company is more well-rounded than 75% of similar companies. A high score indicates that the company is strong across the board; it is attractively priced, growing sustainably, financially stable, and well-regarded by the market. Learn more.

Become an Obermatt subscriber and see all of the similar stocks here.

OTHER FEATURES

Use the Platform to its Fullest

The Obermatt Advantage

Ready to Elevate Your Investing?
Get Started Today

Choose the Obermatt subscription that best fits your needs.


30-day money back guarantee. Your subscription will renew until you cancel it, which you can do at any time.

What Our Customers Say

See how Obermatt improved their investing:

Review us See More Google Reviews